Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Filapixant (BAY1902607) in Healthy Men
NCT03212586Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in refractory chronic cough (RCC) comparing Dose escalation BAY1902607 with Dose escalation Placebo (2 arms). Primary endpoints: Number of subjects with treatment-emergent adverse events up to 11 weeks, Number of subjects with severity of treatment-emergent adverse events up to 11 weeks and 1 more. Started Jul 2017; status: completed.
02
Drugs
filapixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT03212586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212586.